Report cover image

Global Acinetobacter Infections Treatment Market Analysis and Forecast 2026-2032

Publisher APO Research, Inc.
Published Jan 02, 2026
Length 198 Pages
SKU # APRC20822714

Description

Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or “species” of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.

Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings.

Acinetobacter is often resistant to many commonly prescribed antibiotics. Decisions on treatment of infections with Acinetobacter should be made on a case-by-case basis by a healthcare provider. Acinetobacter infection typically occurs in ill patients and can either cause or contribute to death in these patients.

In the American market, Major manufacturers include Entasis Therapeutics, Roche, Adenium Biotech, Vaxdyn, Hsiri Therapeutics, Aridis Pharmaceuticals, and Legochem Biosciences, Atterx Biotherapeutics, Achaogen, Peptilogics, Sealife Pharma, Shionogi, Techulon and Tetraphase Pharmaceuticals, among others. Entasis Therapeutics, Roche and Adenium Biotech are the top 3 players of Acinetobacter Infections Treatment, with about 66% market shares.

Report Includes

This report presents an overview of global market for Acinetobacter Infections Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Acinetobacter Infections Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Acinetobacter Infections Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Acinetobacter Infections Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Acinetobacter Infections Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Acinetobacter Infections Treatment revenue, projected growth trends, production technology, application and end-user industry.

Acinetobacter Infections Treatment Segment by Company

Entasis Therapeutics
Roche
Adenium Biotech
Vaxdyn
Hsiri Therapeutics
Aridis Pharmaceuticals
LegoChem Biosciences
Atterx Biotherapeutics
Achaogen
Peptilogics
Sealife PHARMA
Shionogi
Techulon
Tetraphase Pharmaceuticals

Acinetobacter Infections Treatment Segment by Type

Sulbactam
Carbapenems
Aminoglycosides
Polymyxins
Tetracyclines
Others

Acinetobacter Infections Treatment Segment by Pipeline
ETX2514
Nacubactam RG6080
Arenicin
VXD-001
Small Molecule Antibiotic
AR-401 mAB
LCB01-0371 (PO)
GN-4474
Antibacterial Antibody
Others

Acinetobacter Infections Treatment Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acinetobacter Infections Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Acinetobacter Infections Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acinetobacter Infections Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Acinetobacter Infections Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Acinetobacter Infections Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Acinetobacter Infections Treatment revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

198 Pages
1 Market Overview
1.1 Product Definition
1.2 Acinetobacter Infections Treatment Market by Type
1.2.1 Global Acinetobacter Infections Treatment Market Size by Type, 2021 VS 2025 VS 2032
1.2.2 Sulbactam
1.2.3 Carbapenems
1.2.4 Aminoglycosides
1.2.5 Polymyxins
1.2.6 Tetracyclines
1.2.7 Others
1.3 Acinetobacter Infections Treatment Market by Pipeline
1.3.1 Global Acinetobacter Infections Treatment Market Size by Pipeline, 2021 VS 2025 VS 2032
1.3.2 ETX2514
1.3.3 Nacubactam RG6080
1.3.4 Arenicin
1.3.5 VXD-001
1.3.6 Small Molecule Antibiotic
1.3.7 AR-401 mAB
1.3.8 LCB01-0371 (PO)
1.3.9 GN-4474
1.3.10 Antibacterial Antibody
1.3.11 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Acinetobacter Infections Treatment Market Dynamics
2.1 Acinetobacter Infections Treatment Industry Trends
2.2 Acinetobacter Infections Treatment Industry Drivers
2.3 Acinetobacter Infections Treatment Industry Opportunities and Challenges
2.4 Acinetobacter Infections Treatment Industry Restraints
3 Global Growth Perspective
3.1 Global Acinetobacter Infections Treatment Market Perspective (2021-2032)
3.2 Global Acinetobacter Infections Treatment Growth Trends by Region
3.2.1 Global Acinetobacter Infections Treatment Market Size by Region: 2021 VS 2025 VS 2032
3.2.2 Global Acinetobacter Infections Treatment Market Size by Region (2021-2026)
3.2.3 Global Acinetobacter Infections Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
4.1 Global Acinetobacter Infections Treatment Revenue by Players
4.1.1 Global Acinetobacter Infections Treatment Revenue by Players (2021-2026)
4.1.2 Global Acinetobacter Infections Treatment Revenue Market Share by Players (2021-2026)
4.1.3 Global Acinetobacter Infections Treatment Players Revenue Share Top 10 and Top 5 in 2025
4.2 Global Acinetobacter Infections Treatment Key Players Ranking, 2024 VS 2025 VS 2026
4.3 Global Acinetobacter Infections Treatment Key Players Headquarters & Area Served
4.4 Global Acinetobacter Infections Treatment Players, Product Type & Application
4.5 Global Acinetobacter Infections Treatment Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Acinetobacter Infections Treatment Market CR5 and HHI
4.6.3 2025 Acinetobacter Infections Treatment Tier 1, Tier 2, and Tier 3
5 Acinetobacter Infections Treatment Market Size by Type
5.1 Global Acinetobacter Infections Treatment Revenue by Type (2021 VS 2025 VS 2032)
5.2 Global Acinetobacter Infections Treatment Revenue by Type (2021-2032)
5.3 Global Acinetobacter Infections Treatment Revenue Market Share by Type (2021-2032)
6 Acinetobacter Infections Treatment Market Size by Application
6.1 Global Acinetobacter Infections Treatment Revenue by Application (2021 VS 2025 VS 2032)
6.2 Global Acinetobacter Infections Treatment Revenue by Application (2021-2032)
6.3 Global Acinetobacter Infections Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
7.1 Entasis Therapeutics
7.1.1 Entasis Therapeutics Company Information
7.1.2 Entasis Therapeutics Business Overview
7.1.3 Entasis Therapeutics Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
7.1.4 Entasis Therapeutics Acinetobacter Infections Treatment Product Portfolio
7.1.5 Entasis Therapeutics Recent Developments
7.2 Roche
7.2.1 Roche Company Information
7.2.2 Roche Business Overview
7.2.3 Roche Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
7.2.4 Roche Acinetobacter Infections Treatment Product Portfolio
7.2.5 Roche Recent Developments
7.3 Adenium Biotech
7.3.1 Adenium Biotech Company Information
7.3.2 Adenium Biotech Business Overview
7.3.3 Adenium Biotech Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
7.3.4 Adenium Biotech Acinetobacter Infections Treatment Product Portfolio
7.3.5 Adenium Biotech Recent Developments
7.4 Vaxdyn
7.4.1 Vaxdyn Company Information
7.4.2 Vaxdyn Business Overview
7.4.3 Vaxdyn Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
7.4.4 Vaxdyn Acinetobacter Infections Treatment Product Portfolio
7.4.5 Vaxdyn Recent Developments
7.5 Hsiri Therapeutics
7.5.1 Hsiri Therapeutics Company Information
7.5.2 Hsiri Therapeutics Business Overview
7.5.3 Hsiri Therapeutics Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
7.5.4 Hsiri Therapeutics Acinetobacter Infections Treatment Product Portfolio
7.5.5 Hsiri Therapeutics Recent Developments
7.6 Aridis Pharmaceuticals
7.6.1 Aridis Pharmaceuticals Company Information
7.6.2 Aridis Pharmaceuticals Business Overview
7.6.3 Aridis Pharmaceuticals Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
7.6.4 Aridis Pharmaceuticals Acinetobacter Infections Treatment Product Portfolio
7.6.5 Aridis Pharmaceuticals Recent Developments
7.7 LegoChem Biosciences
7.7.1 LegoChem Biosciences Company Information
7.7.2 LegoChem Biosciences Business Overview
7.7.3 LegoChem Biosciences Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
7.7.4 LegoChem Biosciences Acinetobacter Infections Treatment Product Portfolio
7.7.5 LegoChem Biosciences Recent Developments
7.8 Atterx Biotherapeutics
7.8.1 Atterx Biotherapeutics Company Information
7.8.2 Atterx Biotherapeutics Business Overview
7.8.3 Atterx Biotherapeutics Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
7.8.4 Atterx Biotherapeutics Acinetobacter Infections Treatment Product Portfolio
7.8.5 Atterx Biotherapeutics Recent Developments
7.9 Achaogen
7.9.1 Achaogen Company Information
7.9.2 Achaogen Business Overview
7.9.3 Achaogen Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
7.9.4 Achaogen Acinetobacter Infections Treatment Product Portfolio
7.9.5 Achaogen Recent Developments
7.10 Peptilogics
7.10.1 Peptilogics Company Information
7.10.2 Peptilogics Business Overview
7.10.3 Peptilogics Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
7.10.4 Peptilogics Acinetobacter Infections Treatment Product Portfolio
7.10.5 Peptilogics Recent Developments
7.11 Sealife PHARMA
7.11.1 Sealife PHARMA Company Information
7.11.2 Sealife PHARMA Business Overview
7.11.3 Sealife PHARMA Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
7.11.4 Sealife PHARMA Acinetobacter Infections Treatment Product Portfolio
7.11.5 Sealife PHARMA Recent Developments
7.12 Shionogi
7.12.1 Shionogi Company Information
7.12.2 Shionogi Business Overview
7.12.3 Shionogi Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
7.12.4 Shionogi Acinetobacter Infections Treatment Product Portfolio
7.12.5 Shionogi Recent Developments
7.13 Techulon
7.13.1 Techulon Company Information
7.13.2 Techulon Business Overview
7.13.3 Techulon Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
7.13.4 Techulon Acinetobacter Infections Treatment Product Portfolio
7.13.5 Techulon Recent Developments
7.14 Tetraphase Pharmaceuticals
7.14.1 Tetraphase Pharmaceuticals Company Information
7.14.2 Tetraphase Pharmaceuticals Business Overview
7.14.3 Tetraphase Pharmaceuticals Acinetobacter Infections Treatment Revenue and Gross Margin (2021-2026)
7.14.4 Tetraphase Pharmaceuticals Acinetobacter Infections Treatment Product Portfolio
7.14.5 Tetraphase Pharmaceuticals Recent Developments
8 North America
8.1 North America Acinetobacter Infections Treatment Revenue (2021-2032)
8.2 North America Acinetobacter Infections Treatment Revenue by Type (2021-2032)
8.2.1 North America Acinetobacter Infections Treatment Revenue by Type (2021-2026)
8.2.2 North America Acinetobacter Infections Treatment Revenue by Type (2027-2032)
8.3 North America Acinetobacter Infections Treatment Revenue Share by Type (2021-2032)
8.4 North America Acinetobacter Infections Treatment Revenue by Pipeline (2021-2032)
8.4.1 North America Acinetobacter Infections Treatment Revenue by Pipeline (2021-2026)
8.4.2 North America Acinetobacter Infections Treatment Revenue by Pipeline (2027-2032)
8.5 North America Acinetobacter Infections Treatment Revenue Share by Pipeline (2021-2032)
8.6 North America Acinetobacter Infections Treatment Revenue by Country
8.6.1 North America Acinetobacter Infections Treatment Revenue by Country (2021 VS 2025 VS 2032)
8.6.2 North America Acinetobacter Infections Treatment Revenue by Country (2021-2026)
8.6.3 North America Acinetobacter Infections Treatment Revenue by Country (2027-2032)
8.6.4 United States
8.6.5 Canada
8.6.6 Mexico
9 Europe
9.1 Europe Acinetobacter Infections Treatment Revenue (2021-2032)
9.2 Europe Acinetobacter Infections Treatment Revenue by Type (2021-2032)
9.2.1 Europe Acinetobacter Infections Treatment Revenue by Type (2021-2026)
9.2.2 Europe Acinetobacter Infections Treatment Revenue by Type (2027-2032)
9.3 Europe Acinetobacter Infections Treatment Revenue Share by Type (2021-2032)
9.4 Europe Acinetobacter Infections Treatment Revenue by Pipeline (2021-2032)
9.4.1 Europe Acinetobacter Infections Treatment Revenue by Pipeline (2021-2026)
9.4.2 Europe Acinetobacter Infections Treatment Revenue by Pipeline (2027-2032)
9.5 Europe Acinetobacter Infections Treatment Revenue Share by Pipeline (2021-2032)
9.6 Europe Acinetobacter Infections Treatment Revenue by Country
9.6.1 Europe Acinetobacter Infections Treatment Revenue by Country (2021 VS 2025 VS 2032)
9.6.2 Europe Acinetobacter Infections Treatment Revenue by Country (2021-2026)
9.6.3 Europe Acinetobacter Infections Treatment Revenue by Country (2027-2032)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
9.6.9 Spain
9.6.10 Netherlands
9.6.11 Switzerland
9.6.12 Sweden
9.6.13 Poland
10 China
10.1 China Acinetobacter Infections Treatment Revenue (2021-2032)
10.2 China Acinetobacter Infections Treatment Revenue by Type (2021-2032)
10.2.1 China Acinetobacter Infections Treatment Revenue by Type (2021-2026)
10.2.2 China Acinetobacter Infections Treatment Revenue by Type (2027-2032)
10.3 China Acinetobacter Infections Treatment Revenue Share by Type (2021-2032)
10.4 China Acinetobacter Infections Treatment Revenue by Pipeline (2021-2032)
10.4.1 China Acinetobacter Infections Treatment Revenue by Pipeline (2021-2026)
10.4.2 China Acinetobacter Infections Treatment Revenue by Pipeline (2027-2032)
10.5 China Acinetobacter Infections Treatment Revenue Share by Pipeline (2021-2032)
11 Asia (Excluding China)
11.1 Asia Acinetobacter Infections Treatment Revenue (2021-2032)
11.2 Asia Acinetobacter Infections Treatment Revenue by Type (2021-2032)
11.2.1 Asia Acinetobacter Infections Treatment Revenue by Type (2021-2026)
11.2.2 Asia Acinetobacter Infections Treatment Revenue by Type (2027-2032)
11.3 Asia Acinetobacter Infections Treatment Revenue Share by Type (2021-2032)
11.4 Asia Acinetobacter Infections Treatment Revenue by Pipeline (2021-2032)
11.4.1 Asia Acinetobacter Infections Treatment Revenue by Pipeline (2021-2026)
11.4.2 Asia Acinetobacter Infections Treatment Revenue by Pipeline (2027-2032)
11.5 Asia Acinetobacter Infections Treatment Revenue Share by Pipeline (2021-2032)
11.6 Asia Acinetobacter Infections Treatment Revenue by Country
11.6.1 Asia Acinetobacter Infections Treatment Revenue by Country (2021 VS 2025 VS 2032)
11.6.2 Asia Acinetobacter Infections Treatment Revenue by Country (2021-2026)
11.6.3 Asia Acinetobacter Infections Treatment Revenue by Country (2027-2032)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Acinetobacter Infections Treatment Revenue (2021-2032)
12.2 SAMEA Acinetobacter Infections Treatment Revenue by Type (2021-2032)
12.2.1 SAMEA Acinetobacter Infections Treatment Revenue by Type (2021-2026)
12.2.2 SAMEA Acinetobacter Infections Treatment Revenue by Type (2027-2032)
12.3 SAMEA Acinetobacter Infections Treatment Revenue Share by Type (2021-2032)
12.4 SAMEA Acinetobacter Infections Treatment Revenue by Pipeline (2021-2032)
12.4.1 SAMEA Acinetobacter Infections Treatment Revenue by Pipeline (2021-2026)
12.4.2 SAMEA Acinetobacter Infections Treatment Revenue by Pipeline (2027-2032)
12.5 SAMEA Acinetobacter Infections Treatment Revenue Share by Pipeline (2021-2032)
12.6 SAMEA Acinetobacter Infections Treatment Revenue by Country
12.6.1 SAMEA Acinetobacter Infections Treatment Revenue by Country (2021 VS 2025 VS 2032)
12.6.2 SAMEA Acinetobacter Infections Treatment Revenue by Country (2021-2026)
12.6.3 SAMEA Acinetobacter Infections Treatment Revenue by Country (2027-2032)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.